CRISPR

The CRISPR-Cas9 gene editing technology was developed by Jennifer Doudna and Emmanuelle Charpentier, who were awarded the 2020 Nobel Prize in Chemistry for this work.

CRISPR is a gene-editing technology derived from the bacterial immune system, whose core components are nuclease proteins such as Cas9.

Claude agents discovered an abnormal repetitive DNA sequence with a structure highly similar to CRISPR; human scientists verified and confirmed it as a real biological system not previously defined, naming it ART.

The matching between guide RNA and the target sequence is not absolutely precise and may cause unintended cutting at sites with similar sequences (off-target effects), thereby triggering insertion-deletion mutations or even cancer risk.

CRISPR gene editing technology relies on guide RNA to direct Cas nucleases to target DNA sequences for cutting.

A single CRISPR edit is easy; what is difficult is modifying hundreds or thousands of sites simultaneously without triggering off-target effects and genomic instability, which is also an important reason why AI was introduced to optimize editing strategies.

Colossal Biosciences was founded by Ben Lamm and George Church, with the core goal of using CRISPR gene editing, stem cell technology and synthetic biology methods to bring extinct species back to Earth.

In the de-extinction pathway, CRISPR is responsible for changing, synthetic biology is responsible for building and regulating, and AI is responsible for searching for feasible solutions among the vast space of possible options; de-extinction is seen as a systems engineering effort highly dependent on interdisciplinary infrastructure.

In de-extinction scenarios, the value of CRISPR lies in precise rewriting: researchers use the genome of a closely related species (such as the Asian elephant) as the chassis and edit in, one by one, the key difference sites inferred from the residual DNA of the extinct species (such as the woolly mammoth).

The value of many important scientific discoveries (such as the theory of relativity and CRISPR gene-editing technology) takes decades to become apparent and is difficult to accurately assess at the time of their emergence

The scientists associated with CRISPR received the Nobel Prize in Chemistry in 2020.

Anthropic announced that Claude found a clue to a new defense system with repetitive sequences in vast DNA data, structurally similar to CRISPR-related mechanisms, though its specific function remains unclear.

The specific function of ART is currently unclear, and there is no evidence that it can be used for gene editing in the same way as CRISPR.

The enzyme system located by Claude has a long repetitive DNA array immediately adjacent to its gene, an arrangement that is the hallmark organizational form of CRISPR systems.

Multiple CRISPR-based therapies have been approved and brought to market for treating genetic diseases such as sickle cell disease.

The few known systems with CRISPR-like characteristics are all capable of cutting, copying, and pasting DNA.

CRISPR was first incidentally observed in bacterial genomes in 1987, and its immune function was not elucidated until 2007.

The core logic of the CRISPR system is that guide RNA is responsible for targeting the DNA sequence, while the Cas protein is responsible for executing the cut.

CRISPR is an adaptive immune system used by bacteria and archaea to defend against viruses.

Class 2 systems, which include Cas9, Cas12, and Cas13, have become the mainstay of gene-editing tools due to their simple architecture requiring only a single effector protein.